Phathom Pharmaceuticals

PHAT

Börsenwert 560 Mio. $

Three scientific presentations will highlight new analyses of VOQUEZNA® (vonoprazan) in GERD, including real-world patient characteristics, efficacy across BMI subgroups, and cost-effectiveness in Erosive Esophagitis FLORHAM PARK, N.J., Oct. 08, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, today announced its participation in the American College of Gastroenterology (ACG) 2026 Annual Scientific Meeting, being held October 9-14 in Nashville, Tennessee.

Initiation of registrational Phase 3 study of VOQUEZNA® (vonoprazan) for as-needed (PRN) use in Non-Erosive Reflux Disease (NERD) builds on previously reported positive Phase 2 data Topline results expected in the first quarter of 2028 pHalcon-NERD-302, if successful, is intended to support a potential VOQUEZNA label expansion to include as-needed treatment of heartburn episodes in patients with Non-Erosive GERD, a treatment regimen of interest to patients for which proton pump inhibitors (PPIs) are not currently approved in the U.S. FLORHAM PARK, N.J., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal diseases, today announced the initiation of patient screening in pHalcon-NERD-302, a registrational Phase 3 study evaluating an as-needed (PRN or on-demand) investigational dosing regimen of VOQUEZNA® (vonoprazan) tablets in adults with Non-Erosive Gastroesophageal Reflux Disease, or Non-Erosive GERD (NERD).

LOS ANGELES--(BUSINESS WIRE)---- $PHAT--PHAT Investors Have Opportunity to Join Phathom Pharmaceuticals, Inc. Fraud Investigation with SBS Law.

Phathom Pharmaceuticals is executing a specialist-focused strategy, targeting gastroenterologists to drive VOQUEZNA adoption and move toward sustainable profitability. Second-quarter 2026 revenue grew 88% to $74.3M, SG&A fell, and management forecasts 2026 revenue of $310–$325M with an 80% gross margin, signaling operating leverage. PHAT's commercial runway is supported by $182.5M in cash and improved operating cash flows, but revenue-interest financing remains a material risk.

FLORHAM PARK, N.J., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on commercializing and developing novel treatments for gastrointestinal (GI) diseases, announced today that members of its management team are scheduled to participate in the following upcoming investor conferences in September:

Phathom Pharmaceuticals' revised FY 2026 revenue outlook of $310 million -- $325 million came in below the roughly $332 million -- $334 million analysts were modeling, and PHAT shares sold off on the news Phathom Pharmaceuticals' revised FY 2026 revenue outlook of $310 million -- $325 million came in below the roughly $332 million -- $334 million analysts were modeling, and PHAT shares sold off on the news

NEW YORK--(BUSINESS WIRE)--Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) shareholders took losses after the Company lowered its full-year 2026 revenue guidance to $310 million–$325 million from its previously issued $320 million–$345 million range, falling below Wall Street consensus estimates of approximately $332 million. If you suffered a loss on your Phathom Pharmaceuticals investment, you are encouraged to click here to submit your information. You may also contact Joseph E. Levi, Esq. via.

Phathom Pharmaceuticals, Inc. (PHAT) Q2 2026 Earnings Call Transcript

Phathom Pharmaceuticals guided FY 2026 revenue as high as $345 million while building out a sales force of more than 290 representatives. The revised outlook now tops out at $325 million, and PHAT shareholders absorbed the decline.

Phathom Pharmaceuticals NASDAQ: PHAT reported second-quarter 2026 revenue growth of 88% year over year and said it achieved positive operating profit excluding stock-based compensation for the first time in its history, reaching the milestone one quarter ahead of its prior plan.